Abstract
The MLL-partial tandem duplication (MLL-PTD),characterized by the internal duplication of exons 3-9 or 3-11 in the MLL gene, produces an elongated protein, and is considered as a gain-of-function mutation. The MLL-PTD is primarily found in elderly patients with myelodysplastic syndromes and acute myeloid leukemiaas well as healthy individuals.Previously we showed that Mll-PTD knock-in (MllPTD/WT) mice presented enhanced self-renewal of hematopoietic stem cells (HSCs) and partially blocked differentiation of hematopoietic stem/progenitor cells (HSPCs). Interestingly, Mll-PTD increased the protein level of HIF1A in HSPCs, which is critical for enhanced self-renewal of HSCs. In the current study, we investigated the mechanisms for HIF1A activation by Mll-PTD.
In normoxia, HIF1A is hydroxylated by prolyl hydroxylases (PHD), resulting in rapid protein degradation via ubiquitination. PHD is one of the well-known enzymes whose activity is dependent on the cellular level of α-ketoglutarate (α-KG), one of the metabolites in the tricarboxylic acid (TCA) cycle. Accumulation of subsequent metabolites of α-KG, such as succinate, fumarate, and malate, inhibits activity of α-KG-dependent enzymes. Indeed, mitochondrial dysfunction is known to result in accumulation of TCA cycle intermediates, leading to activation of HIF signaling. Thus, we first examined if Mll-PTD induces the alteration of mitochondrial functions. Interestingly, cellular respiration and activity of mitochondrial complexes (I, II, and III) were significantly decreased in HSPCs of MllPTD/WT mice, while the copy number of mitochondrial DNA was not altered. These results indicate that suppression of mitochondrial activity is not due to the decrease of the total mitochondria. We also examined mRNA expression levels of several major TCA cycle enzymes, and found that succinate dehydrogenase (Sdh) complex (Sdha, Sdhb, and Sdhd) was significantly downregulated in MllPTD/WT HSPCs. SDH is a critical TCA cycle enzyme which converts succinate to fumarate. Inactivation of SDH is known to result in impairment of mitochondrial biogenesis, a blockade of the TCA cycle, and accumulation of TCA cycle metabolites.
We next quantified metabolites in glycolysis and TCA cycle in the plasma from WT control and MllPTD/WT mice. NMR analysis revealed that succinate, fumarate, and malate were increased in the plasma of MllPTD/WT mice. Especially, the ratios of fumarate and malate to α-KG were both significantly increased in MllPTD/WT compared to WT control. Indeed, post-α-KG metabolites increased HIF1A protein in human cord blood CD34+cells in vitro, indicating that higher levels of succinate, fumarate, and malate to α-KG levels stabilize HIF1A. We also confirmed that knockdown of Sdh increased the HIF1A protein level in murine cell line in normoxia. These results indicate that downregulation of Sdh in MllPTD/WT is one of the mechanisms for suppression of mitochondrial activity, leading to pseudohypoxia and HIF1A activation.
Besides PHD, TET and histone lysine demethylases are also α-KG-dependent enzymes. We found that in MllPTD/WT HSPCs, the 5-methylcitosine (5-mC) level was increased in genomic DNA, and trimethylation levels at H3K4, H3K9, H3K36 and H3K79 were also increased. Collectively, these results suggest that metabolic pseudohypoxia due to lower mitochondrial activity not only activates HIF1A signaling but also induces hypermethylation in DNA and histones, through suppression of α-KG-dependent PHD and demethylases.
In summary, we demonstrate that through suppression of mitochondrial complex II, Mll-PTD causes pseudohypoxia and hypermethylation of the epigenome, which may contribute to expansion of premalignant clones and accumulation of additional mutations in those cells. Interestingly, it has been proposed that IDH mutations are involved in tumorigenesis in leukemias and brain tumors through a similar mechanism. Moreover, loss-of-function mutations of the TCA cycle enzymes, SDH complex, and fumarate hydratase, are frequently found in various solid tumors associated with pseudohypoxia and hypermethylation phenotypes. Further investigations of the impact of metabolic-rewiring-mediated pseudohypoxia/hypermethylation on tumorigenesis may lead to the development of novel therapeutic strategies to prevent the onset and/or the progression of various types of malignant diseases.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.